鲁商福瑞达医药股份有限公司董事会 关于 2024 年度独立董事独立性情况的专项报告 根据《上市公司独立董事管理办法》《上海证券交易所股票上市规则》《上海 证券交易所上市公司自律监管指引第 1 号——规范运作》等要求，公司董事会就 公司在任独立董事宿玉海、朱德胜的独立性情况进行评估并出具如下专项意见。 经核查公司独立董事宿玉海、朱德胜的任职经历以及签署的相关自查文件， 上述人员未在公司担任除独立董事以外的任何职务，也未在公司主要股东公司担 任任何职务，与公司以及主要股东之间不存在利害关系或其他可能妨碍其进行独 立客观判断的关系，因此，公司独立董事符合《上市公司独立董事管理办法》《上 海证券交易所上市公司自律监管指引第 1 号——规范运作》中对独立董事独立性 的相关要求。 鲁商福瑞达医药股份有限公司董事会 2025 年 3 月 22 日 ...

证券代码：600223 证券简称：福瑞达 编号：临 2025-005 ●鲁商福瑞达医药股份有限公司（以下简称"公司"）提请股东大会批准公司 2025 年度新增担保预计额度及相关安排，预计 2025 年度对外担保额不超过人民币 17.4362 亿元，以上担保额度包括新增及存续的担保，该额度可在授权期限内滚动循环使用。 ●公司 2023 年第一次临时股东大会审批通过《关于公司重大资产出售完成后新 增关联交易及关联担保的议案》，根据公司重大资产出售相关安排，公司对置出地产 公司的担保由对内向子公司的担保变更为对外向关联方的担保，该部分担保由上市公 司控股股东山东省商业集团有限公司提供反担保，在上述担保的借款到期时，公司将 不再为标的公司提供后续担保。截至本公告披露日，上述关联担保余额为 5.4362 亿 元。 ●除上述关联担保外，公司无其他对外担保。 ●公司无逾期对外担保的情况。 鲁商福瑞达医药股份有限公司 关于公司 2025 年度担保预计额度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ●公司 202 ...

证券代码：600223 证券简称：福瑞达 编号：临 2025-010 公司基于实际经营情况及行业市场变化等因素的影响，根据《企业会计准则》 等相关会计政策规定，为客观、公允地反映公司截至 2024 年 12 月 31 日的财务 状况及 2024 年度的经营成果，公司基于谨慎性原则对各项应收账款、存货、合 同资产等进行全面充分的评估和分析，根据减值测试结果对其中存在减值迹象的 资产计提了减值准备。本期计提的减值准备总额为 33,734,106.98 元。 二、计提资产减值准备的具体情况说明 鲁商福瑞达医药股份有限公司 关于 2024 年度计提资产减值准备的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 鲁商福瑞达医药股份有限公司（以下简称"公司"或"本公司"）根据《企 业会计准则》及公司财务制度等相关规定，对公司合并报表范围内的资产进行了 全面清查，以 2024 年 12 月 31 日为基准日对 2024 年财务报告合并报表范围内相 关资产进行减值测试并计提减值准备。现将公司 2024 年计提资产减值准备的相 关情况公 ...

关于鲁商福瑞达医药股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审核报告 上会师报字(2025)第 2121 号 会计师事务所(特殊善通合 i Eertified Public Accountants (Shecial General Pan 鲁商福瑞达医药股份有限公司 2024 年度非经营性资金占用及其他关联资金往来情况汇总表的 专项审核报告 上会师报字(2025)第 2121 号 中国 上海 鲁商福瑞达医药股份有限公司全体股东; 我们接受委托,依据《中国注册会计师执业准则》审计了鲁商福瑞达医药股份 有限公司(以下简称"贵公司")2024年度的财务报表,包括 2024 年 12 月 31 日的合 并及公司资产负债表,2024年度的合并及公司利润表、合并及公司现金流量表、合 并及公司所有者权益变动表及财务报表附注,并于 2025年 3 月 20 日出具了审计报告 (报告书编号为:上会师报字(2025)第 2118 号)。在此基础上,我们审核了后附的贵 公司管理层编制的"鲁商福瑞达医药股份有限公司 2024 年度非经营性资金占用及其 他关联资金往来情况汇总表"(以下简称"汇总表")。 贵公司 ...

经审议，会议通过以下议案并形成如下决议： 一、全票通过《2024 年度监事会工作报告》，并提交 2024 年年度股东大会。 二、全票通过《2024 年度内部控制评价报告》，认为公司出具的《2024 年度 内部控制评价报告》能够全面、真实、准确地反映公司内部控制的实际情况，详 见上海证券交易所网站 http://www.sse.com.cn。 证券代码：600223 证券简称：福瑞达 编号：临 2025-011 鲁商福瑞达医药股份有限公司 第十二届监事会第四次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 鲁商福瑞达医药股份有限公司第十二届监事会第四次会议于 2025 年 3 月 10 日发出通知，并于 2025 年 3 月 20 日在公司会议室召开。会议由监事会主席吕元 忠先生主持，会议应到监事 3 名，实到监事 3 名，符合《公司法》和公司章程规 定。 2、公司《2024 年年度报告》的内容和格式符合中国证监会和上海证券交易 所的各项规定，所包含的信息从各个方面真实地反映出公司 2024 年度的经营管 理和 ...

鲁商福瑞达医药股份有限公司 第十二届董事会独立董事专门会议决议 鲁商福瑞达医药股份有限公司（以下简称"公司"）第十二届董事会独立董事专 门会议于 2025 年 3 月 10 日发出通知，并于 2025 年 3 月 20 日在公司会议室召开。 经过半数独立董事共同推举，本次会议由独立董事宿玉海召集和主持，本次会议应 参会独立董事 2 名，实际参加表决的独立董事 2 名，本次会议的召集、召开符合《中 华人民共和国公司法》《上市公司独立董事管理办法》《公司章程》《独立董事工作制 度》等有关规定，会议合法有效。 经参会独立董事审议，一致通过以下议案并形成如下决议： 一、通过《关于公司 2025 年度日常关联交易预计发生金额的议案》，独立董事 认为：根据公司经营的需要，公司（包括下属子公司）将与公司控股股东山东省商 业集团有限公司及其关联企业在提供或接受劳务、采购或销售商品、房屋租赁等方 面发生日常经营性关联交易，并遵循客观、公正的原则和市场化定价方式进行，未 损害公司其他股东的利益。上述关联交易未影响公司的独立性，公司主要业务亦未 因上述关联交易而对关联方形成依赖。同意将该议案提交公司第十二届董事会第四 次会议审议， ...

证券代码：600223 证券简称：福瑞达 编号：临 2025-003 1 六、全票通过《2024 年度内部控制评价报告》，该议案已经公司董事会审 计委员会审议通过，详见上海证券交易所网站 http://www.sse.com.cn。 鲁商福瑞达医药股份有限公司 第十二届董事会第四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 鲁商福瑞达医药股份有限公司第十二届董事会第四次会议于2025年3月10日 发出通知，并于2025年3月20日在公司会议室召开。本次董事会应到董事5名，实 到董事5名，同时监事会成员和部分高级管理人员列席本次会议，符合《公司法》 和公司章程规定。 会议由董事长贾庆文先生主持，经参会董事审议表决，通过以下议案并形成 如下决议： 一、全票通过《2024年度董事会工作报告》，并提交公司2024年年度股东大 会审议。 二、全票通过《2024年度总经理业务报告》。 三、全票通过《2024年度独立董事述职报告》，并提交公司2024年年度股东 大会听取,详见上海证券交易所网站http://www.ss ...

Financial Performance - The net profit attributable to the parent company for 2024 is CNY 243,525,296, with the parent company achieving a net profit of CNY 161,150,457.99[6]. - The company's operating revenue for 2024 was CNY 3,982,577,119.73, a decrease of 13.02% compared to 2023[23]. - Net profit attributable to shareholders for 2024 was CNY 243,525,296.00, down 19.73% from the previous year[23]. - The net profit after deducting non-recurring gains and losses increased by 54.54% to CNY 214,624,949.50 compared to 2023[23]. - The total profit for the year was CNY 346 million, down 16.14% compared to the previous year[68]. - The company’s net assets attributable to shareholders grew by 2.24% to CNY 4.11 billion[68]. - The company reported a significant reduction in short-term borrowings by 69.92%, down to CNY 212,116,144.16, as a result of repaying bank loans[95]. Dividend Distribution - The total cash dividend for the year, including the interim distribution, amounts to CNY 111,822,565.25, representing 45.92% of the net profit attributable to shareholders[7]. - The proposed cash dividend distribution is CNY 0.6 per 10 shares, totaling CNY 60,994,126.50, subject to shareholder approval[6]. - The company announced a cash dividend of CNY 111,822,565.25, which accounts for 45.92% of the net profit attributable to ordinary shareholders in the consolidated financial statements, amounting to CNY 243,525,296.00[195]. - The cumulative cash dividend over the last three accounting years is CNY 213,479,442.75, with an average net profit of CNY 197,455,937.04, resulting in a cash dividend ratio of 108.11%[197]. Assets and Liabilities - Total assets at the end of 2024 were CNY 6,000,330,923.23, a decrease of 23.25% from the end of 2023[23]. - The company’s cash and cash equivalents increased by 70.04% to CNY 2,947,718,857.86, primarily due to the receipt of remaining payments from the real estate business divestiture[95]. - Accounts receivable decreased by 38.09% to CNY 42,208,300.08, mainly due to the settlement of notes[95]. - The remaining undistributed profit for the parent company is CNY 478,213,079.30, to be carried forward to future years[6]. Research and Development - The company invested 199 million yuan in R&D in 2024, representing a year-on-year increase of 20.05%[38]. - The number of R&D personnel is 430, accounting for 11.85% of the total workforce[89]. - Total R&D investment amounted to 198.72 million RMB, which is 4.99% of total revenue, with 16.08% of R&D costs capitalized[88]. - The company launched over 140 new cosmetic products and received 64 new patent authorizations, including 42 invention patents[38]. Market Performance - In 2024, the cosmetics segment achieved revenue of 2.475 billion yuan, a year-on-year increase of 2.46%, with a gross margin of 62.57%[35]. - The Yilian brand generated revenue of 963 million yuan, up 12.36% year-on-year, while the Ai'er Doctor brand saw a revenue decline of 3.48% to 1.301 billion yuan[35]. - The pharmaceutical segment reported revenue of 512 million yuan, a decrease of 1.41%, with a gross margin of 52.32%[36]. - The company achieved a sales growth of 37% for its Tongxuan Li Fei capsules, with over 360,000 boxes sold[36]. Corporate Governance - The company held two shareholder meetings during the reporting period, ensuring all shareholders, especially minority shareholders, could exercise their voting rights[154]. - The board of directors convened 9 meetings during the reporting period, maintaining compliance with legal and regulatory requirements[154]. - The company emphasizes the importance of intellectual property protection and the commercialization of research outcomes[52]. - The company’s governance structure includes independent directors and supervisors to ensure compliance and accountability[168]. Strategic Initiatives - The company is focused on technological innovation and high-end transformation in the raw materials sector, driven by the increasing demand for natural and green ingredients[45]. - The company is actively expanding its market presence through strategic partnerships and product innovation, aiming to capture emerging market opportunities in both cosmetics and pharmaceuticals[44]. - The company is implementing a "1234" high-quality innovation development strategy, focusing on enhancing its leading position in hyaluronic acid and optimizing its pharmaceutical and cosmetics segments[135]. - The company is committed to integrating raw material and formulation development, accelerating the registration of pharmaceutical-grade hyaluronic acid domestically and internationally[137]. Environmental and Social Responsibility - The company emphasizes environmental protection and safety management, committing to enhance training and risk control measures[150]. - The company is committed to green development and increasing investment in environmental protection to ensure compliance with emission standards[150]. - The company is closely monitoring policy changes in the cosmetics and pharmaceutical sectors to mitigate potential risks and adapt its strategies accordingly[145]. Human Resources - The total number of employees across the parent company and major subsidiaries is 3,630, with 1,235 in production, 560 in sales, and 1,280 in technical roles[184][185]. - The company has established a talent development mechanism to enhance the quality of its workforce and ensure a steady supply of key personnel[187][188]. - The company has implemented a performance-based salary system, linking compensation to operational performance and market competitiveness[186].

证券代码：600223 证券简称：福瑞达 编号：临 2025-004 鲁商福瑞达医药股份有限公司 2024 年度利润分配预案公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ●本次利润分配方案不触及《上海证券交易所股票上市规则（2024 年 4 月 修订）》第 9.8.1 条第一款第（八）项规定的可能被实施其他风险警示的情形。 一、利润分配预案内容 （一）利润分配方案的具体内容 经上会会计师事务所（特殊普通合伙）审计，公司 2024 年度实现归属于母 公司所有者的净利润 243,525,296.00 元，母公司 2024 年度实现净利润 161,150,457.99 元，母公司期末可供股东分配的利润为 539,207,205.80 元。 ●每股派发现金红利人民币 0.06 元(含税)。 ●本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体日期 将在权益分派实施公告中明确。 ●在实施权益分派的股权登记日前公司总股本发生变动的，拟维持分配总额 不变，相应调整每股分配比例，并另行公告具体调整情况。 ...

Investment Rating - The report recommends a "buy" rating for the cosmetics and medical beauty sectors, highlighting a favorable outlook for 2025 due to improved consumer expectations and policy support [4][6]. Core Insights - The report emphasizes that the cosmetics sector will focus on three key elements: domestic brands, segmentation, and cost-effectiveness, with a projected steady growth in demand for 2025 [4][6]. - The medical beauty industry is expected to benefit from improved income expectations, with domestic companies poised to become major competitors in the light medical beauty segment [4][6]. - E-commerce is identified as a growth area, with new consumption models and brands emerging to drive development [4][6]. Summary by Sections 1. Industry Performance Review - The beauty and personal care sector has not achieved excess returns in 2025 due to trading disruptions, but is expected to rebound with policy support [7][8]. - The SW beauty index has seen a growth of 0.6% since the beginning of 2025, underperforming compared to the broader A-share index [8][10]. 2. Cosmetics Sector - The report forecasts a recovery in the cosmetics demand in 2025, with a focus on high cost-performance brands benefiting from consumer preferences [15][18]. - Domestic brands are gaining market share, with significant growth in the skincare market, where domestic brands now occupy four out of the top ten positions [18][19]. - The report highlights the success of domestic brands in e-commerce platforms, particularly during promotional events, indicating a strong competitive position against international brands [21][22]. 3. Medical Beauty Sector - The medical beauty market is transitioning from a blue ocean to a red ocean, with domestic companies expanding their product lines and research pipelines [4][6]. - Key recommendations include focusing on companies with strong product pipelines and high profitability, such as Ai Meike [4][6]. 4. E-commerce Sector - The report suggests that the e-commerce sector will continue to thrive with the rise of new consumption models and brands, particularly benefiting from the growth of domestic brands [4][6]. 5. Key Company Recommendations - The report recommends several companies based on their brand matrix and growth potential, including Shangmei Co., Pulaile, and others in the cosmetics sector [4][6]. - In the medical beauty sector, Ai Meike is highlighted as a key player, with a focus on companies with strong product offerings and research capabilities [4][6].